Co-Authors
This is a "connection" page, showing publications co-authored by MILIND JAVLE and CHING-WEI DAVID TZENG.
Connection Strength
1.119
-
Utilizing Patient-derived Xenografts to Model Precision Oncology for Biliary Tract Cancer. Clin Cancer Res. 2024 Nov 08.
Score: 0.062
-
Measurable imaging-based changes in enhancement of intrahepatic cholangiocarcinoma after radiotherapy reflect physical mechanisms of response. medRxiv. 2024 Sep 12.
Score: 0.062
-
Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. J Immunother Cancer. 2024 Feb 02; 12(2).
Score: 0.059
-
Revisiting the Malignant Masquerade at the Liver Hilum: Have We Made Progress? Ann Surg Oncol. 2024 May; 31(5):3062-3068.
Score: 0.059
-
Effects of a Pragmatic Home-based Exercise Program Concurrent With Neoadjuvant Therapy on Physical Function of Patients With Pancreatic Cancer: The PancFit Randomized Clinical Trial. Ann Surg. 2023 07 01; 278(1):22-30.
Score: 0.056
-
Brain Metastases from Biliary Tract Cancer: Case Series and Clinicogenomic Analysis. Oncologist. 2023 04 06; 28(4):327-332.
Score: 0.056
-
Definitive Liver Radiotherapy for Intrahepatic Cholangiocarcinoma with Extrahepatic Metastases. Liver Cancer. 2023 Aug; 12(3):198-208.
Score: 0.056
-
Neoadjuvant chemotherapy for high-risk intrahepatic cholangiocarcinoma - does pathologic response mean better outcomes? HPB (Oxford). 2023 04; 25(4):472-480.
Score: 0.055
-
Single-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic Cancer. Cancer Discov. 2022 10 05; 12(10):2330-2349.
Score: 0.054
-
Radiographic and Serologic Response to First-Line Chemotherapy in Unresected Localized Pancreatic Cancer. J Natl Compr Canc Netw. 2022 08; 20(8):887-897.e3.
Score: 0.053
-
Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase 1 Trial and Imaging-based Biomarker Validation. Int J Radiat Oncol Biol Phys. 2022 11 01; 114(3):444-453.
Score: 0.053
-
Ablative liver radiotherapy for unresected intrahepatic cholangiocarcinoma: Patterns of care and survival in the United States. Cancer. 2022 07 01; 128(13):2529-2539.
Score: 0.052
-
Benchmarking Outcomes after Ablative Radiotherapy for Molecularly Characterized Intrahepatic Cholangiocarcinoma. J Pers Med. 2021 Dec 01; 11(12).
Score: 0.051
-
Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients. Cancer Med. 2021 08; 10(15):5041-5050.
Score: 0.049
-
Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. Ann Surg. 2021 04 01; 273(4):806-813.
Score: 0.049
-
Time to Rethink Upfront Surgery for Resectable Intrahepatic Cholangiocarcinoma? Implications from the Neoadjuvant Experience. Ann Surg Oncol. 2021 Oct; 28(11):6725-6735.
Score: 0.048
-
Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2020 09 01; 155(9):832-839.
Score: 0.047
-
Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma. Ann Surg. 2020 06; 271(6):996-1002.
Score: 0.046
-
First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol. 2019 Feb; 26(2):619-627.
Score: 0.041
-
Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma. Cancer Med. 2018 10; 7(10):4880-4892.
Score: 0.041
-
Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2017 Nov 01; 152(11):1048-1056.
Score: 0.038
-
The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy. Ann Surg Oncol. 2015 Dec; 22 Suppl 3:S1221-8.
Score: 0.033